London Calling 2025 - Speakers
Speakers
Check out the line up of speakers at London Calling 2025.
A
)
Arianna CerutiLeipzig University, Germany
)
Ana Flavia PeresBarretos Cancer Hospital, Brazil
)
Adrien LegerDirector, Modified Base Research, Oxford Nanopore Technologies
)
Alberto MagiUniversity of Florence, Italy
)
Alimat OyawoyeNIHR BioResource, UK
)
Albert Perlas PuenteHelmholtz Munich, Germany
)
Alex TrotterDevelopment Scientist – Translational Development, Oxford Nanopore Technologies
)
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
)
Anna WierczeikoInstitute for Human Genetics, University Medical Center Mainz, Germany
B
)
Benjamin C. ReinerUniversity of Pennsylvania, USA
)
Basharat BhatSher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST), India
)
Bryant CatanoSenior Product Support Scientist, Oxford Nanopore Technologies
)
Brendan KeatingNYU Langone Health, USA
C
)
Chris AlderBioinformatician, Oxford Nanopore Technologies
)
Clive BrownChief Technology, Innovation, and Product Officer, Oxford Nanopore Technologies
)
Chloé BaumPasteur Institute, France
)
Dr. Charles K. CooperbioMérieux, France
)
Chloe GoldsmithTranslational Health Research Institute, Western Sydney University, Australia
)
Chris SeymourVP, Advanced Platform Development, Oxford Nanopore Technologies
)
Cora VacherAssociate Director, Market Segment, Oxford Nanopore Technologies
)
)
E
)
Eloisa ArbustiniIRCCS Foundation Policlinico San Matteo, Italy
)
Prof. Emma BapleUniversity of Exeter and South West NHS Genomics Laboratory Hub, UK
)
Eva Maria NovoaCentre for Genomic Regulation, Spain
)
)
H
)
Dr. Helen Bulbeckbrainstrust, UK
)
Hagan BayleyUniversity of Oxford, UK
)
Haoyu ChengYale University, USA
I
)
Ilaria CasconeUniversity of Naples Federico II, Italy
)
Ira DevesonGarvan Institute of Medical Research, Australia
)
Ivo GutNational Centre for Genomic Analysis, Spain
J
)
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
)
Javeria AijazIndus Hospital & Health Network, Pakistan
)
Judith BreuerUCL Institute of Child Health, UK
)
James BrayerDirector, Business Development, Nanopore Developers & Compatible Products Program, Oxford Nanopore Technologies
)
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
)
Joy GoffenaUniversity of Washington, USA
)
Jonathon HillWasatch BioLabs, USA
)
Jeff NivalaUniversity of Washington, USA
)
Jason WilliamsCold Spring Harbor Laboratory, USA
)
Jose-Crispin Zavala AlvaradoPathoQuest, France
K
)
Kieran O'NeillCanada's Michael Smith Genome Sciences Centre, Canada
)
Kathy StirrupsNIHR BioResource, UK
L
)
Lyn ChittyGreat Ormond Street NHS Foundation Trust & UCL Great Ormond Street Institute of Child Health, UK
)
Lucas Esteban WangePompeu Fabra University, Spain
)
Lakmal JayasingheChief Scientific Officer, Oxford Nanopore Technologies
)
Lennart KesterPrincess Máxima Center, The Netherlands
M
)
Mark AkesonUniversity of California, Santa Cruz, USA
)
Micah HoylmanUniversity of Nebraska Medical Center, USA
)
Mahreen KhanThe Hospital for Sick Children, Canada
)
Megan L. NoonanWashington University School of Medicine in St. Louis, USA
)
Mashiat Mimosa University of Toronto, Canada
)
Marcel NelenUMC Utrecht, The Netherlands
)
Michelle NgMichael Smith Laboratories, Canada
)
Matilda TierneyKing’s College London, UK
)
Michael WileyUniversity of Nebraska Medical Center, USA
N
)
Nadia DavidsonThe Walter and Eliza Hall Institute, Australia
)
Nathaniel EdisisBoston Children's Hospital, USA
)
Nathalie KingstonNIHR BioResource, UK
)
Nick OwensUniversity of Exeter, UK
P
)
Paul ArvidsonGenomics England & SWAN, UK
)
Pamela GanNalaGenetics, Singapore
)
Pauline Luise PfudererCRUK Cambridge Centre & Department of Pathology, University of Cambridge, UK
)
Patrick MurphyMarket Segment Manager for Single Cell, Oxford Nanopore Technologies
)
Prasad SarashettiA*STAR Genome Institute of Singapore, Singapore
)
Paula Saffie-AwadSanta Maria Clinic, Chile
R
)
Rafi AhmadUniversity of Inland Norway & University of Tromsø, Norway & University of Southampton, UK
)
Dr. Rahul BatraGuy's and St Thomas' NHS Foundation Trust UK
)
Ruben CoolsVIB-KU Leuven, Belgium
)
Rajesh PandeyCSIR-Institute of Genomics and Integrative Biology, India
)
Rute RegoInnovPlantProtect, Portugal
)
Rachel Samson P.Cranfield University, UK
)
Rhydian WindsorResearch Scientist, Machine Learning, Oxford Nanopore Technologies
S
)
Salvatore BenfattoDana-Farber Cancer Institute, USA
)
Sam DavisPrincipal Scientist, Machine Learning, Oxford Nanopore Technologies
)
Sarah FramptonUniversity of Southampton, UK
)
Sirisha HeskethClinical Bioinformatician, Oxford Nanopore Technologies
)
Skarphedinn HalldorssonOslo University Hospital, Norway
)
Steven HairNewcastle University, UK
)
Susie LeeTechnical Product Manager, Basecalling and Models, Oxford Nanopore Technologies
)
Sebastian LunkeVictorian Clinical Genetics Services, Australia
)
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
)
Sayonika MohantaStrategic Marketing Manager — Methylation, Oxford Nanopore Technologies
)
Steven RobbinsAustralian Centre for Ecogenomics, Australia
)
Spike WillcocksChief Strategy Officer, Oxford Nanopore Technologies
T
)
Thomas AlexanderUniversity of North Carolina, USA
)
Tomasz DobrzyckiField Applications Scientist, New Product Introduction, Oxford Nanopore Technologies
)
Tina HanTwist Bioscience
)
Thidathip WongsurawatMahidol University, Thailand
)
)
)
)
)
)
)
)
)
Oxford Nanopore Technologies
Claire Anderson
)
- Job title
- Institution
- University College London, UK
- Biography
Claire Anderson did an undergraduate degree in biomedical science and went on to specialise in developmental biology during her postgraduate studies and post-doctoral work. Claire is now a research assistant in the lab of Professor Mina Ryten — funded by The Michael J. Fox Foundation for Parkinson’s Research and Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network initiative. Claire uses long-read sequencing technologies to understand the pathological mechanisms of Parkinson’s disease and other neurodegenerative disorders.
Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in-vitro diagnostic devices in some jurisdictions, please check individual product labelling. Oxford Nanopore Technologies present the materials of third parties within the user community acknowledging that those materials belong to and are the true statements and representations of those third parties. Oxford Nanopore Technologies make no endorsements of the materials shown and the statements made.
